# Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

> **NCT00425750** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** bortezomib
- **DRUG:** docetaxel
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00425750
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425750, "Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00425750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*